EXAS * logo

Exact Sciences BMV:EXAS * Stock Report

Last Price

Mex$1.05k

Market Cap

Mex$171.5b

7D

0%

1Y

n/a

Updated

23 Mar, 2025

Data

Company Financials +

Exact Sciences Corporation

BMV:EXAS * Stock Report

Market Cap: Mex$171.5b

EXAS * Stock Overview

Provides cancer screening and diagnostic test products in the United States and internationally. More details

EXAS * fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 71.5% below our estimate of its fair value

Earnings are forecast to grow 85.11% per year

Analysts in good agreement that stock price will rise by 52.2%

Risk Analysis

Shares are highly illiquid


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Exact Sciences Corporation Competitors

Innovent Biologics

SEHK:1801

HK$66.5b

Chongqing Zhifei Biological Products

SZSE:300122

CN¥59.2b

Swedish Orphan Biovitrum

OM:SOBI

SEK 99.7b

Exelixis

NasdaqGS:EXEL

US$10.3b

Price History & Performance

Summary of share price highs, lows and changes for Exact Sciences
Historical stock prices
Current Share PriceUS$1,050.00
52 Week HighUS$1,211.50
52 Week LowUS$760.88
Beta1.25
1 Month Change0.67%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO-23.36%

Recent News & Updates

Recent updates

Shareholder Returns

EXAS *MX BiotechsMX Market
7D0%0%0%
1Yn/a0%0%

Return vs Industry: Insufficient data to determine how EXAS * performed against the MX Biotechs industry.

Return vs Market: Insufficient data to determine how EXAS * performed against the MX Market.

Price Volatility

Is EXAS *'s price volatile compared to industry and market?
EXAS * volatility
EXAS * Average Weekly Movementn/a
Biotechs Industry Average Movement0%
Market Average Movement0%
10% most volatile stocks in MX Market0%
10% least volatile stocks in MX Market0%

Stable Share Price: EXAS *'s share price has been volatile over the past 3 months compared to the MX market.

Volatility Over Time: Insufficient data to determine EXAS *'s volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19956,950Kevin Conroywww.exactsciences.com

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer.

Exact Sciences Corporation Fundamentals Summary

How do Exact Sciences's earnings and revenue compare to its market cap?
EXAS * fundamental statistics
Market capMex$171.48b
Earnings (TTM)-Mex$20.82b
Revenue (TTM)Mex$55.83b

3.1x

P/S Ratio

-8.2x

P/E Ratio

Is EXAS * overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EXAS * income statement (TTM)
RevenueUS$2.76b
Cost of RevenueUS$840.15m
Gross ProfitUS$1.92b
Other ExpensesUS$2.95b
Earnings-US$1.03b

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-5.54
Gross Margin69.55%
Net Profit Margin-37.29%
Debt/Equity Ratio107.0%

How did EXAS * perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 06:01
End of Day Share Price 2025/02/24 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Exact Sciences Corporation is covered by 47 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Bruce JacksonBenchmark Company